Urologic Oncology: Seminars and Original Investigations
Volume 26, Issue 4 , Pages 341-345 , July 2008

Role of neutrophils in BCG immunotherapy for bladder cancer

  • Mark P. Simons, Ph.D.

      Affiliations

    • Department of Urology, University of Iowa, Iowa City, IA 52242, USA
    • ,
  • Michael A. O'Donnell, M.D.

      Affiliations

    • Department of Urology, University of Iowa, Iowa City, IA 52242, USA
    • ,
  • Thomas S. Griffith, Ph.D.

      Affiliations

    • Department of Urology, University of Iowa, Iowa City, IA 52242, USA
    • Interdisciplinary Program in Immunology, University of Iowa, Iowa City, IA 52242, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-319-335-7581; fax: +1-319-335-6971.

Received 1 October 2007 ,Revised 1 November 2007 ,Accepted 8 November 2007.

References 

  1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8–29
  2. Utz DC, Farrow GM. Management of carcinoma in situ of the bladder: The case for surgical management. Urol Clin North Am. 1980;7:533–541
  3. Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol. 1976;116:180–183
  4. Schamhart DH, de Boer EC, de Reijke TM, et al. Urinary cytokines reflecting the immunological response in the urinary bladder to biological response modifiers: Their practical use. Eur Urol. 2000;37(Suppl 3):16–23
  5. Prescott S, James K, Hargreave TB, et al. Intravesical Evans strain BCG therapy: Quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol. 1992;147:1636–1642
  6. Lage JM, Bauer WC, Kelley DR, et al. Histological parameters and pitfalls in the interpretation of bladder biopsies in Bacillus Calmette-Guerin treatment of superficial bladder cancer. J Urol. 1986;135:916–919
  7. Ludwig AT, Moore JM, Luo Y, et al. Tumor necrosis factor-related apoptosis-inducing ligand: A novel mechanism for Bacillus Calmette-Guerin-induced antitumor activity. Cancer Res. 2004;64:3386–3390
  8. Simons MP, Moore JM, Kemp TJ, et al. Identification of the mycobacterial subcomponents involved in the release of tumor necrosis factor-related apoptosis-inducing ligand from human neutrophils. Infect Immun. 2007;75:1265–1271
  9. Crispen R. History of BCG and its substrains. Prog Clin Biol Res. 1989;310:35–50
  10. Becich MJ, Carroll S, Ratliff TL. Internalization of Bacille Calmette-Guerin by bladder tumor cells. J Urol. 1991;145:1316–1324
  11. Luo Y, Szilvasi A, Chen X, et al. A novel method for monitoring Mycobacterium bovis BCG trafficking with recombinant BCG expressing green fluorescent protein. Clin Diagn Lab Immunol. 1996;3:761–768
  12. Kavoussi LR, Brown EJ, Ritchey JK, et al. Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa (Requirement for the expression of an antitumor response). J Clin Invest. 1990;85:62–67
  13. Hedges S, Agace W, Svensson M, et al. Uroepithelial cells are part of a mucosal cytokine network. Infect Immun. 1994;62:2315–2321
  14. Thalmann GN, Dewald B, Baggiolini M, et al. Interleukin-8 expression in the urine after bacillus Calmette-Guerin therapy: A potential prognostic factor of tumor recurrence and progression. J Urol. 1997;158:1340–1344
  15. Thalmann GN, Sermier A, Rentsch C, et al. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin. J Urol. 2000;164:2129–2133
  16. Shapiro A, Lijovetzky G, Pode D. Changes of the mucosal architecture and of urine cytology during BCG treatment. World J Urol. 1988;6:61–68
  17. de Boer EC, De Jong WH, Van der Meijden AP, et al. Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-Guerin. Cancer Immunol Immunother. 1991;33:411–416
  18. Godaly G, Proudfoot AE, Offord RE, et al. Role of epithelial interleukin-8 (IL-8) and neutrophil IL-8 receptor A in Escherichia coli-induced transuroepithelial neutrophil migration. Infect Immun. 1997;65:3451–3456
  19. Kemp TJ, Ludwig AT, Earel JK, et al. Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Guérin (BCG) results in the release of functional soluble TRAIL/Apo-2L. Blood. 2005;106:3474–3482
  20. Tecchio C, Huber V, Scapini P, et al. IFNα-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells. Blood. 2004;103:3837–3844
  21. Koga Y, Matsuzaki A, Suminoe A, et al. Neutrophil-derived TNF-related apoptosis-inducing ligand (TRAIL): A novel mechanism of antitumor effect by neutrophils. Cancer Res. 2004;64:1037–1043
  22. Cassatella MA, Huber V, Calzetti F, et al. Interferon-activated neutrophils store a TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) intracellular pool that is readily mobilizable following exposure to proinflammatory mediators. J Leukoc Biol. 2006;79:123–132
  23. Suttmann H, Riemensberger J, Bentien G, et al. Neutrophil granulocytes are required for effective bacillus Calmette-Guerin immunotherapy of bladder cancer and orchestrate local immune responses. Cancer Res. 2006;66:8250–8257
  24. Kamohara H, Matsuyama W, Shimozato O, et al. Regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and TRAIL receptor expression in human neutrophils. Immunology. 2004;111:186–194
  25. Alexandroff AB, Jackson AM, O'Donnell MA, et al. BCG immunotherapy of bladder cancer: 20 years on. Lancet. 1999;353:1689–1694
  26. Yamamura Y, Azuma I, Taniyama T, et al. Immunotherapy of cancer with cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guérin: Experimental and clinical results. Ann NY Acad Sci. 1976;277:209–227
  27. Filion MC, Phillips NC. Therapeutic potential of mycobacterial cell wall-DNA complexes. Expert Opin Investig Drugs. 2001;10:2157–2165
  28. Borregaard N, Heiple JM, Simons ER, et al. Subcellular localization of the b-cytochrome component of the human neutrophil microbicidal oxidase: Translocation during activation. J Cell Biol. 1983;97:52–61
  29. Bohle A, Nowc C, Ulmer AJ, et al. Elevations of cytokines interleukin-1, interleukin-2, and tumor necrosis factor in the urine of patients after intravesical Bacillus Calmette-Guerin immunotherapy. J Urol. 1990;144:59–64
  30. Jackson AM, Alexandroff AB, Kelly RW, et al. Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after Bacillus Calmette-Guerin (BCG) immunotherapy. Clin Exp Immunol. 1995;99:369–375
  31. Joudi FN, Smith BJ, O'Donnell MA. Final results from a national multicenter Phase II trial of combination Bacillus Calmette-Guerin plus interferon α-2B for reducing recurrence of superficial bladder cancer. Urol Oncol. 2006;24:344–348
  32. Faurschou M, Borregaard N. Neutrophil granules and secretory vesicles in inflammation. Microbes Infect. 2003;5:1317–1327

☆ This work was supported by the University of Iowa Infectious Diseases Postdoctoral Training Grant (M.P.S.), Carver Medical Research Initiative Grant administered through the University of Iowa Carver College of Medicine (T.S.G.), and grant CA109446 from the National Cancer Institute (T.S.G.).

PII: S1078-1439(07)00298-0

doi: 10.1016/j.urolonc.2007.11.031

Urologic Oncology: Seminars and Original Investigations
Volume 26, Issue 4 , Pages 341-345 , July 2008

Article Tools